Abigail Struthers focuses her practice on patent litigation in the life sciences sector, combining her experience as a private practitioner with in-house know-how gained from serving as Sandoz’s senior IP litigation counsel to provide clients with business-practical intellectual property solutions.

Ms. Struthers has represented leading pharmaceutical and life sciences clients in disputes relating to biologic drug products, small-molecule pharmaceuticals and drug delivery technology. She has represented both plaintiffs and defendants at every stage of litigation, including trial and appeal, and has practiced in state court, federal court and before the Patent Trial and Appeal Board. Ms. Struthers also regularly advises on intellectual property aspects of corporate mergers and acquisitions and is experienced in conducting patent due diligence investigations.

Experience

  • Sanofi and Regeneron in patent litigation (on remand) in connection with their Praluent® drug product. Amgen Inc. et. al. v. Sanofi et. al. (D. Del.).
  • Sandoz in connection with its Hyrimoz® drug product, a biosimilar to AbbVie Biotechnology’s Humira®; also in inter partes review proceedings challenging Humira® patents and in related Federal Circuit appeals. See, e.g., Sandoz Inc. v. AbbVie Biotechnology Ltd., IPR2017-02105, 02106; Sandoz Inc. v. AbbVie Biotechnology Ltd., Case 2018-2142 (Fed. Cir.).
  • Novartis in multiple Hatch-Waxman patent litigations relating to Novartis' Gleevec® drug product, indicated for the treatment of chronic myeloid leukemia. Novartis Pharmaceuticals Corp. and Novartis AG v. Roxane Laboratories et al. (D. Del.).
  • Novartis in patent litigation relating to leukemia immunotherapy with chimeric antigen receptor modified T-cells. Trustees of the University of Pennsylvania and Novartis Pharmaceuticals Corporation v. St. Jude Children's Research Hospital, Inc. and Juno Therapeutics, Inc. (ED Pa.).
  • Pfizer in patent litigation concerning Pfizer's Celebrex® drug product. G.D. Searle LLC and Pfizer Asia Pacific Pte. Ltd. v. Lupin Pharmaceuticals, Inc., et al. (D. Va.).
  • Sanofi-Aventis, as a member of the trial team, in patent litigation relating to Sanofi's Allegra® drug products. Aventis Pharmaceuticals, Inc. v. Dr. Reddy's Laboratories Ltd. et al. (DNJ).
  • Vivelle Ventures, Noven Pharmaceuticals and Novartis in Hatch-Waxman litigation concerning the Vivelle Dot® transdermal estradiol drug product. Vivelle Ventures, Noven Pharmaceuticals, and Novartis Pharmaceuticals Corporation v. Mylan Technologies, et al. (SDNY).
  • Time Warner Cable in patent litigation relating to on-demand television. Broadband iTV, Inc. v. Hawaiian Telcom, Inc., Oceanic Time Warner Cable LLC and Time Warner Cable, Inc. (D. Haw.).
  • Qinetiq Group in patent litigation relating to metal detector technology. Mednovus, Inc. and First Texas Holdings Corp. v. Qinetiq Group PLC et al. (CD Cal).
  • Butamax and du Pont in patent litigation relating to biofuels technology. Butamax™ Advanced Biofuels LLC and du Pont de Nemours and Company v. Gevo, Inc. (D. Del).
  • CLS Bank International in landmark patent litigation relating to computerized methods of exchanging financial obligations. CLS Bank International v. Alice Corporation Pty. Ltd. (DDC).
  • Roche defendants in patent litigation relating to recombinant human erythropoietin therapy. Amgen v. F. Hoffman-La Roche Ltd., Roche Diagnostics Gmbh, and Hoffman-La Roche Inc. (D. Mass.).
  • Pfizer in first Hatch-Waxman litigation concerning Pfizer's Celebrex® drug product. Pfizer Inc. et al. v. Teva Pharmaceuticals USA, Inc. (DNJ).

Perspectives

PTAB Newsletter
Newsletter

Credentials

Education
  • JD, Fordham University School of Law, 2004, cum laude
  • BA, Neuroscience, Wesleyan University, 1999
Admissions
  • New York
  • US District Court, Eastern District of New York
  • US District Court, Southern District of New York
Activities
  • Treasurer, New York Intellectual Property Association
  • Board Liaison, Women in IP Law Committee
  • Chair, Women in IP Law Committee
Overview

Email Disclaimer